Skip to main content
Erschienen in: Pathology & Oncology Research 1/2018

11.04.2017 | Original Article

Reproducibility and Prognostic Potential of Ki-67 Proliferation Index when Comparing Digital-Image Analysis with Standard Semi-Quantitative Evaluation in Breast Cancer

verfasst von: Balázs Ács, Lilla Madaras, Kristóf Attila Kovács, Tamás Micsik, Anna-Mária Tőkés, Balázs Győrffy, Janina Kulka, Attila Marcell Szász

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

In this study, the reproducibility of Ki-67 proliferation index (KIPI) was investigated by comparing the semi-quantitative (SQ) results of three assessors with those of digital image-analysis (DIA) methods. The prognostic significance of the two approaches was also correlated with clinical outcome. Tissue microarrays of duplicate 2 mm cores were constructed from representative areas of formalin-fixed and paraffin-embedded tumor blocks of 347 breast cancer patients. SQ evaluation of Ki-67 (MIB1 clone) immunostained slides was performed independently by three pathologists. DIA was completed using a fully automated histological pattern and cell recognition module for KIPI detection (DIA-1) and an adjustable module (DIA-2) with the possibility of manual corrections. To compare SQ and DIA evaluations intra-class correlation (ICC) and concordance correlation coefficients (CCC) were determined. The three SQ evaluations demonstrated a remarkable ICC (0.853). Significant difference and poor concordance occurred between SQ-1 and SQ-2 as well as between SQ-1 and SQ-3 (p ≤ 0.001, CCC ≤ 0.827 for both comparisons). Thus, the reference KIPI value (SQ-RV) was generated from the mean values of SQ-2 and SQ-3. SQ-RV and DIA-2 results showed substantial concordance (CCC = 0.963, at p = 0.754), while SQ-RV and DIA-1 values differed (p ≤ 0.001) at only moderate concordance (CCC = 0.906). In multivariate analysis, lymph node status and SQ-2 assessment were significantly associated with clinical outcome (p ≤ 0.012 for both comparisons). Our results confirm that KIPI is a significant prognostic marker in breast cancer, which can be can be reliably reproduced by using an adjustable DIA-2 image analysis module.
Literatur
1.
Zurück zum Zitat Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, Cardoso F (2013) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi7–v23. doi:10.1093/annonc/mdt284 CrossRefPubMed Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, Cardoso F (2013) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi7–v23. doi:10.​1093/​annonc/​mdt284 CrossRefPubMed
3.
Zurück zum Zitat Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31(1):13–20CrossRefPubMed Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31(1):13–20CrossRefPubMed
4.
Zurück zum Zitat Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thurlimann B, Senn HJ (2015) Tailoring therapies-improving the management of early breast cancer: St Gallen international expert Consensus on the Primary therapy of early breast cancer 2015. Ann Oncol 26(8):1533–1546. doi:10.1093/annonc/mdv221 CrossRefPubMedPubMedCentral Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thurlimann B, Senn HJ (2015) Tailoring therapies-improving the management of early breast cancer: St Gallen international expert Consensus on the Primary therapy of early breast cancer 2015. Ann Oncol 26(8):1533–1546. doi:10.​1093/​annonc/​mdv221 CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert Consensus on the Primary therapy of early breast cancer 2013. Ann Oncol 24(9):2206–2223. doi:10.1093/annonc/mdt303 CrossRefPubMedPubMedCentral Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert Consensus on the Primary therapy of early breast cancer 2013. Ann Oncol 24(9):2206–2223. doi:10.​1093/​annonc/​mdt303 CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr, American Society of Clinical Oncology (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312. doi:10.1200/JCO.2007.14.2364 CrossRefPubMed Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr, American Society of Clinical Oncology (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312. doi:10.​1200/​JCO.​2007.​14.​2364 CrossRefPubMed
7.
Zurück zum Zitat Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF (2011) Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst 103(22):1656–1664. doi:10.1093/jnci/djr393 CrossRefPubMedPubMedCentral Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF (2011) Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst 103(22):1656–1664. doi:10.​1093/​jnci/​djr393 CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Polley MY, Leung SC, Gao D, Mastropasqua MG, Zabaglo LA, Bartlett JM, McShane LM, Enos RA, Badve SS, Bane AL, Borgquist S, Fineberg S, Lin MG, Gown AM, Grabau D, Gutierrez C, Hugh JC, Moriya T, Ohi Y, Osborne CK, Penault-Llorca FM, Piper T, Porter PL, Sakatani T, Salgado R, Starczynski J, Laenkholm AV, Viale G, Dowsett M, Hayes DF, Nielsen TO (2015) An international study to increase concordance in Ki67 scoring. Mod Pathol 28(6):778–786. doi:10.1038/modpathol.2015.38 CrossRefPubMed Polley MY, Leung SC, Gao D, Mastropasqua MG, Zabaglo LA, Bartlett JM, McShane LM, Enos RA, Badve SS, Bane AL, Borgquist S, Fineberg S, Lin MG, Gown AM, Grabau D, Gutierrez C, Hugh JC, Moriya T, Ohi Y, Osborne CK, Penault-Llorca FM, Piper T, Porter PL, Sakatani T, Salgado R, Starczynski J, Laenkholm AV, Viale G, Dowsett M, Hayes DF, Nielsen TO (2015) An international study to increase concordance in Ki67 scoring. Mod Pathol 28(6):778–786. doi:10.​1038/​modpathol.​2015.​38 CrossRefPubMed
9.
Zurück zum Zitat Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, Viale G, Zabaglo LA, Penault-Llorca F, Bartlett JM, Gown AM, Symmans WF, Piper T, Mehl E, Enos RA, Hayes DF, Dowsett M, Nielsen TO (2013) An international Ki67 reproducibility study. J Natl Cancer Inst 105(24):1897–1906. doi:10.1093/jnci/djt306 CrossRefPubMedPubMedCentral Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, Viale G, Zabaglo LA, Penault-Llorca F, Bartlett JM, Gown AM, Symmans WF, Piper T, Mehl E, Enos RA, Hayes DF, Dowsett M, Nielsen TO (2013) An international Ki67 reproducibility study. J Natl Cancer Inst 105(24):1897–1906. doi:10.​1093/​jnci/​djt306 CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Luporsi E, Andre F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, Egele C, Poulet B, Clough KB, Crouet H, Fourquet A, Lefranc JP, Mathelin C, Rouyer N, Serin D, Spielmann M, Haugh M, Chenard MP, Brain E, de Cremoux P, Bellocq JP (2012) Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 132(3):895–915. doi:10.1007/s10549-011-1837-z CrossRefPubMed Luporsi E, Andre F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, Egele C, Poulet B, Clough KB, Crouet H, Fourquet A, Lefranc JP, Mathelin C, Rouyer N, Serin D, Spielmann M, Haugh M, Chenard MP, Brain E, de Cremoux P, Bellocq JP (2012) Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 132(3):895–915. doi:10.​1007/​s10549-011-1837-z CrossRefPubMed
13.
Zurück zum Zitat Kayser K, Borkenfeld S, Kayser G (2012) How to introduce virtual microscopy (VM) in routine diagnostic pathology: constraints, ideas, and solutions. Anal Cell Pathol (Amst) 35(1):3–10. doi:10.3233/acp-2011-0044 CrossRef Kayser K, Borkenfeld S, Kayser G (2012) How to introduce virtual microscopy (VM) in routine diagnostic pathology: constraints, ideas, and solutions. Anal Cell Pathol (Amst) 35(1):3–10. doi:10.​3233/​acp-2011-0044 CrossRef
15.
Zurück zum Zitat Laurinavicius A, Plancoulaine B, Laurinaviciene A, Herlin P, Meskauskas R, Baltrusaityte I, Besusparis J, Dasevicius D, Elie N, Iqbal Y, Bor C (2014) A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue. Breast Cancer Res 16(2):R35. doi:10.1186/bcr3639 CrossRefPubMedPubMedCentral Laurinavicius A, Plancoulaine B, Laurinaviciene A, Herlin P, Meskauskas R, Baltrusaityte I, Besusparis J, Dasevicius D, Elie N, Iqbal Y, Bor C (2014) A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue. Breast Cancer Res 16(2):R35. doi:10.​1186/​bcr3639 CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Ruifrok AC, Johnston DA (2001) Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 23(4):291–299PubMed Ruifrok AC, Johnston DA (2001) Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 23(4):291–299PubMed
18.
Zurück zum Zitat Altman DG (1990) Practical statistics for medical research. Chapman and Hall, London Altman DG (1990) Practical statistics for medical research. Chapman and Hall, London
19.
Zurück zum Zitat McBride GB (2005) A proposal for strength-of-agreement criteria for Lin’s Concordance Correlation Coefficient. NIWA Client Report: HAM2005–062 McBride GB (2005) A proposal for strength-of-agreement criteria for Lin’s Concordance Correlation Coefficient. NIWA Client Report: HAM2005–062
20.
Zurück zum Zitat Kontzoglou K, Palla V, Karaolanis G, Karaiskos I, Alexiou I, Pateras I, Konstantoudakis K, Stamatakos M (2013) Correlation between Ki67 and breast cancer prognosis. Oncology 84(4):219–225. doi:10.1159/000346475 CrossRefPubMed Kontzoglou K, Palla V, Karaolanis G, Karaiskos I, Alexiou I, Pateras I, Konstantoudakis K, Stamatakos M (2013) Correlation between Ki67 and breast cancer prognosis. Oncology 84(4):219–225. doi:10.​1159/​000346475 CrossRefPubMed
21.
Zurück zum Zitat Mikami Y, Ueno T, Yoshimura K, Tsuda H, Kurosumi M, Masuda S, Horii R, Toi M, Sasano H (2013) Interobserver concordance of Ki67 labeling index in breast cancer: Japan breast cancer research group Ki67 ring study. Cancer Sci 104(11):1539–1543. doi:10.1111/cas.12245 CrossRefPubMed Mikami Y, Ueno T, Yoshimura K, Tsuda H, Kurosumi M, Masuda S, Horii R, Toi M, Sasano H (2013) Interobserver concordance of Ki67 labeling index in breast cancer: Japan breast cancer research group Ki67 ring study. Cancer Sci 104(11):1539–1543. doi:10.​1111/​cas.​12245 CrossRefPubMed
23.
Zurück zum Zitat Cserni G, Voros A, Liepniece-Karele I, Bianchi S, Vezzosi V, Grabau D, Sapino A, Castellano I, Regitnig P, Foschini MP, Zolota V, Varga Z, Figueiredo P, Decker T, Focke C, Kulka J, Kaya H, Reiner-Concin A, Amendoeira I, Callagy G, Caffrey E, Wesseling J, Wells C (2014) Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values. Breast 23(3):259–263. doi:10.1016/j.breast.2014.02.003 CrossRefPubMed Cserni G, Voros A, Liepniece-Karele I, Bianchi S, Vezzosi V, Grabau D, Sapino A, Castellano I, Regitnig P, Foschini MP, Zolota V, Varga Z, Figueiredo P, Decker T, Focke C, Kulka J, Kaya H, Reiner-Concin A, Amendoeira I, Callagy G, Caffrey E, Wesseling J, Wells C (2014) Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values. Breast 23(3):259–263. doi:10.​1016/​j.​breast.​2014.​02.​003 CrossRefPubMed
24.
Zurück zum Zitat Voros A, Csorgo E, Kovari B, Lazar P, Kelemen G, Rusz O, Nyari T, Cserni G (2015) Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy. Pathol Oncol Res 21(1):147–155. doi:10.1007/s12253-014-9800-z CrossRefPubMed Voros A, Csorgo E, Kovari B, Lazar P, Kelemen G, Rusz O, Nyari T, Cserni G (2015) Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy. Pathol Oncol Res 21(1):147–155. doi:10.​1007/​s12253-014-9800-z CrossRefPubMed
25.
Zurück zum Zitat Maeda I, Abe K, Koizumi H, Nakajima C, Tajima S, Aoki H, Tsuchiya J, Tsuchiya S, Tsuchiya K, Shimo A, Tsugawa K, Ueno T, Tatsunami S, Takagi M (2015) Comparison between Ki67 labeling index determined using image analysis software with virtual slide system and that determined visually in breast cancer. Breast Cancer. doi:10.1007/s12282-015-0634-7 Maeda I, Abe K, Koizumi H, Nakajima C, Tajima S, Aoki H, Tsuchiya J, Tsuchiya S, Tsuchiya K, Shimo A, Tsugawa K, Ueno T, Tatsunami S, Takagi M (2015) Comparison between Ki67 labeling index determined using image analysis software with virtual slide system and that determined visually in breast cancer. Breast Cancer. doi:10.​1007/​s12282-015-0634-7
26.
Zurück zum Zitat Klauschen F, Wienert S, Schmitt WD, Loibl S, Gerber B, Blohmer JU, Huober J, Rudiger T, Erbstosser E, Mehta K, Lederer B, Dietel M, Denkert C, von Minckwitz G (2015) Standardized Ki67 diagnostics using automated scoring-clinical validation in the GeparTrio breast cancer study. Clin Cancer Res 21(16):3651–3657. doi:10.1158/1078-0432.ccr-14-1283 CrossRefPubMed Klauschen F, Wienert S, Schmitt WD, Loibl S, Gerber B, Blohmer JU, Huober J, Rudiger T, Erbstosser E, Mehta K, Lederer B, Dietel M, Denkert C, von Minckwitz G (2015) Standardized Ki67 diagnostics using automated scoring-clinical validation in the GeparTrio breast cancer study. Clin Cancer Res 21(16):3651–3657. doi:10.​1158/​1078-0432.​ccr-14-1283 CrossRefPubMed
28.
Zurück zum Zitat Joshi S, Watkins J, Gazinska P, Brown JP, Gillett CE, Grigoriadis A, Pinder SE (2015) Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value. BMC Cancer 15:546. doi:10.1186/s12885-015-1531-3 CrossRefPubMedPubMedCentral Joshi S, Watkins J, Gazinska P, Brown JP, Gillett CE, Grigoriadis A, Pinder SE (2015) Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value. BMC Cancer 15:546. doi:10.​1186/​s12885-015-1531-3 CrossRefPubMedPubMedCentral
Metadaten
Titel
Reproducibility and Prognostic Potential of Ki-67 Proliferation Index when Comparing Digital-Image Analysis with Standard Semi-Quantitative Evaluation in Breast Cancer
verfasst von
Balázs Ács
Lilla Madaras
Kristóf Attila Kovács
Tamás Micsik
Anna-Mária Tőkés
Balázs Győrffy
Janina Kulka
Attila Marcell Szász
Publikationsdatum
11.04.2017
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 1/2018
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0220-8

Weitere Artikel der Ausgabe 1/2018

Pathology & Oncology Research 1/2018 Zur Ausgabe

Letter to the Editor

Tribute to Prof. George Klein

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.